Anti-inflammatory drugs and the kidney

International Journal of Artificial Organs

Volumn 30, Issue 12, 2007, Pages 1042-1046

  House, Andrew A ^a,c   Oliveira, S Silva ^b   Ronco, C ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b SAN BORTOLO HOSPITAL   (Italy)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Nephrotoxicity; Nonsteroidal anti inflammatory drugs; Renal prostaglandins; Vasomotor acute kidney injury

Indexed keywords

ANTI-INFLAMMATORY DRUGS; CLINICAL PRACTICES; CLINICAL SYNDROMES; NEPHROTOXICITY; NON-STEROIDAL ANTI-INFLAMMATORY DRUGS; NONSTEROIDAL ANTI-INFLAMMATORY DRUGS; RENAL FAILURE; RENAL PROSTAGLANDIN; SIDE EFFECT; VASOMOTOR ACUTE KIDNEY INJURY;

DRUG INTERACTIONS;

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PHENACETIN; POTASSIUM SPARING DIURETIC AGENT;

ACUTE KIDNEY FAILURE; AGING; ALCOHOL ABUSE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; COMORBIDITY; DEHYDRATION; DIABETES MELLITUS; DRUG POTENTIATION; DRUG USE; DRUG WITHDRAWAL; ELDERLY CARE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART FUNCTION; HEMODYNAMIC STRESS; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY PAPILLA NECROSIS; NEPHROTOXICITY; PATHOGENESIS; PATIENT MONITORING; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SODIUM RETENTION; WATER RETENTION;

EID: 38849103028     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880703001203     Document Type: Review

References (22)

1. Wali RK, Henrich WL. Recent developments in toxic nephropathy. Curr Opin Nephrol Hypertens 2002; 11: 155-63.
2. Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis 1996; 28 (Suppl 1): S56-62.
3. Kleinknecht D, Landais P, Goldfarb B. Analgesic and nonsteroidal anti-inflammatory drug-associated acute renal failure: a prospective collaborative study. Clin Nephrol 1986; 25: 275-81.
4. Huerta C, Castellsague J, Varas-Lorenzo C, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 2005; 45: 531-9.
5. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 1994; 331: 1675-9.
6. Gambaro G, Perazella MA. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med 2003; 253: 643-52.
7. Garella S, Matarese RA. Renal effects of prostaglandins and clinical adverse effects of nonsteroidal anti-inflammatory agents. Medicine (Baltimore) 1984; 63: 165-81.
8. Schneider V, Levesque LE, Zhang B, et al. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. Am J Epidemiol 2006; 164: 881-9.
9. Dzau VJ. Vascular and renal prostaglandins as counter-regulatory systems in heart failure. Eur Heart J 1988; 9 (Suppl H): 15-9.
10. Audoly LP, Rocca B, Fabre JE, et al. Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE-III are mediated via the thromboxane A receptor in vivo. Circulation 2000; 101: 2833-40.
11. Gooch K, Culleton BF, Manns BJ, et al. NSAID use and progression of chronic kidney disease. Am J Med 2007; 120: 280.e1-7.
12. Hickey EJ, Raje RR, Reid VE, et al. Diclofenac induced in vivo nephrotoxicity may involve oxidative stress-mediated massive genomic DNA fragmentation and apoptotic cell death. Free Radic Biol Med 2001; 31: 139-52.
13. Molitoris BA, Sutton TA. Endothelial injury and dysfunction: role in the extension phase of acute renal failure. Kidney Int 2004; 66: 496-9.
14. Kaushal GP, Basnakian AG, Shah SV. Apoptotic pathways in ischemic acute renal failure. Kidney Int 2004; 66: 500-6.
15. Yin C, Knudson CM, Korsmeyer SJ, Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 1997; 385: 637-40.
16. Kandasamy K, Srinivasula SM, Alnemri ES, et al: Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. Cancer Res 63:1712-1721, 2003
17. Brezin JH, Katz SM, Schwartz AB, Chinitz JL. Reversible renal failure and nephrotic syndrome associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1979; 301: 1271-3.
18. Singhal PC, Faulkner M, Venkatesan J, Molho L. Hypersensitivity angiitis associated with naproxen. Ann Allergy 63; 1989: 107-9.
19. Breyer MD, Hao C, Qi Z: Cyclooxygenase-2 selective inhibitors and the kidney. Curr Opin Crit Care 2001; 7: 393-400.
20. Harris RC, Jr: Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol 2002; 89: 10D-7.
21. Frishman WH. Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am J Cardiol 2002; 89: 18D-25.
22. Findling JW, Beckstrom D, Rawsthorne L, et, al. Indomethacin-induced hyperkalemia in three patients with gouty arthritis. JAMA 1980; 244: 1127-8.